Tag:
Sanofi
Latest Headlines
Latest Headlines
UPDATED: NIH makes progress on universal flu vaccine
A universal flu vaccine is the holy grail of influenza immunizations. The yearly process of making educated guesses about the upcoming flu season would end, replaced by a vaccine for many of the strains. It is a massive challenge, but one that Sanofi and others have taken up.
Sanofi, France remain at odds over fate of 600 R&D jobs
Sanofi CEO Chris Viehbacher has reviled the company's research site in Toulouse, France as unproductive and overly costly. But try as he may, he can't seem to rid himself and the company of the center and its 612 researchers, a move Viehbacher initially advocated as part of 2,500 job reduction plan in the mother country.
Sanofi balks on jobs promises at R&D site in Toulouse
Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner
India sets controversial price caps on 650 drugs
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
Sanofi highlights positive PhIII study for myelofibrosis contender
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Report: Roche looking to unload blood glucose meter business
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
Sanofi hunts for clinical trial recruits in growing social network
Sanofi has gone online in search of patients for clinical trials, partnering with the social network PatientsLikeMe and a healthcare nonprofit to inform patients about trials and match them with appropriate studies from the French drug giant.
France slaps Sanofi with $53M fine for 'disparaging' Plavix generics
The drugmaker has been fined by the French Competition Authority for "disparaging" generic copies of its now-off-patent bloodthinner, Plavix.
UPDATED: Third Rock Ventures expands roster with Alnylam's CEO and Genzyme/Sanofi vet
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.
WHO clears way for Sanofi's antimalarial ingredient
The World Health Organization (WHO) has cleared the way for artemisinin-combination therapy (ACT) manufacturers to use Sanofi's semi-synthetic active ingredient. WHO acceptance comes one month after Sanofi began producing the active as an alternative to plant-derived artemisinin.
